What Pear Therapeutics’ Bankruptcy Has Left the DTX Industry to Ponder
MedCity News
JUNE 12, 2023
During Covid-19, governing agencies loosened regulatory requirements and increased incentives for DTx. The conventional pharmaceutical approach failed an industry leader due to government inaction and lack of private payer support. This strategy eliminates the per-unit sticker price, but at the cost of losing the FDA credibility.
Let's personalize your content